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1. Introduction 
Ovarian cancer is the second most common gynecological malignancy occurring in about 
200,000 women worldwide out of which close to 125,000 die from the disease. In the United 
States, ovarian cancer is detected in about 21,000 women resulting in about 14,000 deaths 
(Parkin, Bray et al. 2005; Sankaranarayanan and Ferlay 2006; Jemal, Siegel et al. 2009). The 
majority of women diagnosed with ovarian cancer, are usually diagnosed in the advanced 
stage of the disease (Yancik 1993). This chapter highlights major developments that have led 
to emergence of neoadjuvant chemotherapy (NAC) as a useful strategy for managing 
advanced ovarian carcinoma.  
For many years, primary cytoreductive surgery (PCS) followed by adjuvant chemotherapy 
with a platinum based agent has been the standard of care for management of advanced 
ovarian cancer (Griffiths 1975; 1994; Hoskins, McGuire et al. 1994; Curtin, Malik et al. 1997; 
Berek, Trope et al. 1999; Bristow, Tomacruz et al. 2002; Kyrgiou, Salanti et al. 2006). The 
Gynecologic Oncology Group (GOG) defines optimal cytoreduction as leaving residual 
disease less than one centimeter in maximum tumor diameter. Residual disease after 
cytoreduction is a known risk factor for disease recurrence and poor survival. In a GOG 
study, compared to patients with microscopic residual disease, patients with 0.1 to 1.0 cm 
and >1.0 cm residual disease had an increased risk of recurrence (HR = 1.96; 95% CI, 1.70 to 
2.26; and HR = 2.36; 95% CI, 2.04 to 2.73, respectively) and death (HR = 2.11; 95% CI, 1.78 to 
2.49; P<.001; and HR = 2.47; 95% CI, 2.09 to 2.92, respectively) (Winter, Maxwell et al. 2007).  
However, there are recent studies challenging this GOG definition of optimal cytoreduction. 
These studies have shown even better survival rates when post surgical tumor size is 
reduced to no visible disease. A retrospective study divided the cohort of 465 patients 
undergoing surgery into no visible residual disease, residual tumor size <0.5 centimeter, 0.6-
1 centimeter, 1-2 centimeter or greater than 2 centimeter. The survival outcomes of the above 
five cohorts were 106 months, 66 months, 48 months, 33 months and 34 months respectively. 
The overall survival rate was significantly better in the group cytoreduced to no visible 
disease. The group with residual tumor size <1 cm had better survival outcomes compared 
to group of patients with >1cm residual disease (Chi, Eisenhauer et al. 2006). 
Another study comparing patients that had been cytoreduced to no visible disease to 
patients cytoreduced to less than 1 cm versus more than 1 cm concluded that the former 
group had better overall (OS) and progression free survival (PFS) as well as lesser platinum 
resistance (Eisenhauer, Abu-Rustum et al. 2008).  
Debate exists as to whether the observed survival benefits for cytoreducted patients are a 
function of tumor biology or surgical effort. Hientz et al observed that cytoreduction is 
easier to obtain in young patients with low grade tumor, smaller sized metastases and no 
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ascites (Heintz, Van Oosterom et al. 1988). One study also showed that women who could 
not be optimally debulked had higher frequency of pelvic and paraortic lymph node 
metastases (Burghardt, Girardi et al. 1991). Hacker et al reported that presence of extensive 
metastatic disease was by itself a poor prognostic marker despite optimal cytoreduction 
(Hacker, Berek et al. 1983). Friedlander reported that the size of largest residual tumor was 
not an independent prognostic factor when newer variables such as DNA ploidy were 
included in multivariate analysis. (Friedlander, Hedley et al. 1988)  
2. Neoadjuvant chemotherapy: Role in ovarian cancer 
Neoadjuvant chemotherapy is defined as chemical cytoreduction occurring prior to any 
significant attempt at surgical reduction of the tumor. On the other hand, interval debulking 
surgery (IDS) refers to secondary surgical cytoreduction in patients who could not be 
optimally cytoreducted in the first surgical attempt. This involves administrating 
chemotherapy after primary surgery and then repeating the surgical procedure in hopes of 
achieving optimal cytoreduction. An EORTC study that randomized 319 patients who had 
residual disease of more than 1 centimeter after primary surgery and received three cycles of 
cyclophosphamide and Cisplatin to undergo either debulking surgery or no surgery. 
Progression free survival  and overall survival were both significantly higher in the group 
that underwent interval debulking surgery. However, a large prospective GOG trial showed 
that this approach did not improve progression free survival or overall survival when 
compared to post operative chemotherapy alone (Rose, Nerenstone et al. 2004). 
Neoadjuvant chemotherapy  has been proposed for patients with advanced ovarian cancer 
where the disease extent would deem optimal cytoreduction extremely difficult or 
impossible (Ledermann 2010). Studies have shown that neoadjuvant chemotherapy can 
improve quality of life in patients over an extended period of time. One study analyzing 
quality of life of patients receiving neoadjuvant chemotherapy using EORTC quality of life 
questionnaire as a tool assessing global health, symptom improvement and functional status 
reported that life overall quality of life improved after neoadjuvant chemotherapy and 
continues to improve up to a period of 12 months.  (Chan, Ng et al. 2003).  
2.1 Patient selection 
Several studies have tried to define the group of patients in whom, due to the advanced and 
unresectable nature of their disease, primary surgery would be difficult or have a suboptimal 
result. These patients could potentially benefit from neoadjuvant chemotherapy (Markman 
2010; Weinberg, Rodriguez et al. 2010). Nelson et al. were the first to study CT imaging criteria 
to define cytoreducibility by primary surgery. Forty two patients with epithelial ovarian 
carcinoma underwent preoperative CT scan. Primary tumor was scored as non cytoreducible 
if the following characteristics were present: attachment of omentum to spleen, >2 centimeter 
of disease in mesentery, liver, gallbladder fossa, diaphragm, paraaortic suprarenal lymph 
nodes, and pericardial nodes, pulmonary or pleural involvement. This study concluded that 
CT scan was a sensitive tool to predict optimal cytoreduciblity (sensitivity= 92.3 percent) with 
specificity being 79.3 percent. Addition of Ca-125 to upper limits of 36 units/ml, 65 units/ml 
or 100 units/ml did not enhance CT prediction of accuracy (Chi, Franklin et al. 2004).  
Preliminary studies indicate that higher Ca-125 levels (>2000 U/ml) may be a risk factor for 
suboptimal cytoreduction and hence may prompt initial cytoreduction before proceeding 
with primary surgery. In a retrospective review of 314 patients, 94 patients who received 
neoadjuvant chemotherapy had more advanced disease (p<0.001) and had higher CA-125 
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levels (p<0.001). Optimal cytoreduction rate was significantly higher in the neoadjuvant 
chemotherapy group (81.9% vs. 50%, p<0.001) but progression free survival was similar in 
both groups. However, in patients with CA-125 levels >2000 U/ml, progression free 
survival was significantly higher in neoadjuvant chemotherapy group. (HR= 0.62, 95% CI = 
0.24-0.96, P=0.037)(Kang, Kim et al. 2011).  
Recently, RNA microarray analysis has been used to identify gene expression associated 
with optimal debulking. After looking at more than 22,000 genes in forty four study patients 
by the means of RNA microarray analysis, Berchuck et al were able to identify a set of 32 
genes which are potentially strong predictors of optimal or suboptimal debulking 
(Berchuck, Iversen et al. 2004).  
2.2 Outcomes 
Neoadjuvant chemotherapy followed by surgery has shown to improve perioperative 
outcomes such optimal cytoreduction, decrease blood loss, and reduce length of 
hospitalization. (Fanfani, Ferrandina et al. 2003; Milam, Tao et al. 2011) 
Several small studies of patients with advanced ovarian cancer have demonstrated that 
neoadjuvant chemotherapy is associated with same progression free survival and overall 
survival as the patients treated conventionally.(Giannopoulos, Butler-Manuel et al. 2006) 
(Chambers, Chambers et al. 1990; Schwartz, Chambers et al. 1994) However, there are also 
some studies which show significantly improved survival with neoadjuvant 
chemotherapy.(Hou, Kelly et al. 2007) (Kuhn, Rutke et al. 2001) 
The cost of caring for patients who have had an extensive but suboptimal surgery may be 
greater than those treated with neoadjuvant chemotherapy. (Schwartz, Chambers et al. 1994) 
These studies also demonstrate that neoadjuvant chemotherapy is associated with lesser 
surgical morbidity such as blood loss, shorter operative times and shorter length of hospital 
and ICU stay.(Lawton, Redman et al. 1989; Chambers, Chambers et al. 1990; Jacob, 
Gershenson et al. 1991; Lim and Green 1993; Schwartz, Chambers et al. 1994; Vergote, De 
Wever et al. 1998; Schwartz, Rutherford et al. 1999) One retrospective study of 116 patients 
showed worse outcomes with neoadjuvant chemotherapy with greater survival in primary 
surgery group (53% vs. 30%, p=0.03). However, in this study, patients in the neoadjuvant 
chemotherapy group were significantly older (p<0.001), had higher grade of disease 
(p<0.005) and when adjusted for age and grade, patients there was no difference in overall 
survival (p=0.95) (Steed, Oza et al. 2006). 
The largest randomized control trial to analyze the role of neoadjuvant chemotherapy in 
advanced stage ovarian carcinoma was performed by Vergote et al. In this study, 718 
patients with stage IIIc or IV ovarian carcinoma were randomized to primary debulking 
surgery or neoadjuvant chemotherapy. Primary debulking surgery group had attempt at 
cytoreduction in the beginning followed by 3 cycles of platinum based chemotherapy, 
followed by interval debulking if needed, followed by 3 additional cycles of 
chemotherapy. 704 patients were required in order to show noninferiority with respect to 
survival between primary debulking surgery and neoadjuvant chemotherapy, with a one-
sided type I error of 0.05 and a power of 80%. The expected median survival in the 
primary debulking surgery arm was 31 months. The expected optimal debulking rate (≤ 1 
centimeter) was 50% in the primary debulking surgery. It was found that percentage of 
patients with large size metastases (>10 centimeter and >2 centimeter) was fewer in the 
group that received neoadjuvant chemotherapy. 53 percent of patients in neoadjuvant 
chemotherapy group had no residual disease after interval debulking while the 
corresponding number in primary debulking surgery group was 21 percent only. Optimal 
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cytoreduction defined as residual tumor <1 centimeter could be obtained in 82 percent of 
patients in neoadjuvant chemotherapy group and 46 percent patients in primary 
debulking surgery group. There was lower incidence of post operative mortality and 
morbidity (hemorrhage, fever, fistula formation) in neoadjuvant chemotherapy group. 
Both the groups had similar progression free (12 months) and overall survival (29 months 
for primary debulking surgery vs. 30 months for neoadjuvant chemotherapy, HR 0.98 
(95% C.I. 0.85-1.14)). There did not seem to be a subgroup based on stage III or IV, age, 
WHO performance, histological type, countries with high or low optimal debulking rate 
for which primary debulking surgery or neoadjuvant chemotherapy followed by interval 
debulking surgery result in better survival. In multivariate analysis, optimal debulking 
was the strongest independent prognostic factor for overall survival (p<0.0001). Hence, it 
can be concluded from this study that optimal debulking should remain the goal of every 
surgical effort but the timing of this procedure (primary debulking surgery or interval 
debulking surgery) does not seem to affect outcomes. Due to the lower morbidity of 
interval debulking surgery compared with primary debulking surgery and the similar 
survival, neoadjuvant chemotherapy can be considered a preferred treatment in these 
patients with stage IIIC/IV ovarian cancer. Interval cytoreductive surgery is also 
currently a subject of the Chemotherapy or Upfront surgery in Ovarian Cancer Patients 
(CHORUS) study in Canada and the United Kingdom.  
One possible arguement against neoadjuvant chemotherapy is that it deprives potential 
candidates of intraperitoneal chemotherapy. Studies (Smith, Moon et al. 2009), Barnett abs. 
SGO 2007) have shown that intraperitoneal therapy can be successfully incorporated post-opera-
tively in patients that are able to be optimally debulked following neoadjuvant chemotherapy. 
Intraperitoneal therapy was well tolerated in these studies.(Tiersten, Liu et al. 2009) 
Though there are no standard predictors of response to neoadjuvant chemotherapy, 
reduction in volume of ascites and decreasing Ca-125 values are the most studied 
parameters. A randomized phase 2 multicenter trial evaluated early response criteria and 
surgical outcomes in patients with advanced stage (stage IIIC or IV) ovarian carcinoma with 
large volume ascites treated with neoadjuvant chemotherapy. Patient were randomized into 
receiving 2/6 vs. 3/6 cycles of carboplatin and docetaxel preoperatively and response was 
measured by assessing residual ascites volume and CA-125 levels. It was found that 
reduction in ascites volume to <500ml and CA-125 to <50% of initial value, were predictors 
of good response (Polcher, Mahner et al. 2009).  
Neoadjuvant chemotherapy followed by cytoreductive surgery has shown to yield better 
results in advanced ovarian cancer then compared to chemotherapy only approach. Another 
retrospective study of 129 patients with stage IV ovarian cancer showed that patients who 
were treated with neoadjuvant chemotherapy followed by cytoreductive surgery had a 
median survival of 45.5 months, which was significantly better than patients who did not 
have cytoreductive surgical procedure (15.1 months) (p<0.01)(Rafii, Deval et al. 2007).  
A phase two study to assess the safety and efficacy of neoadjuvant chemotherapy (four 
cycles of carboplatin and paclitaxel) followed by debulking surgery followed by four more 
cycles of chemotherapy for mullerian carcinoma was done in Japan. Out of the fifty-three 
patients who received neoadjuvant chemotherapy, 47 underwent interval debulking surgery 
(89%). Twenty two (42%) patients achieved complete clinical remission which was also the 
primary endpoint. Complete resection of tumor could be performed in 55% (29/53) patients. 
Median overall and progression free survival was 45 and 14 months respectively. Main 
toxicity of chemotherapy regimen was neutropenia (grade 4 in 70% patients) and anemia 
(Onda, Kobayashi et al. 2009).  
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Although, ability of neoadjuvant chemotherapy to help achieve optimal cytoreduction is an 
important end point in most of the above trials, it is important to note that significance of 
achieving optimal surgical cytoreduction is still unclear. Some studies define it to be one of 
the most important indicators of prognosis (Eisenkop, Spirtos et al. 2003; Aletti, Dowdy et 
al. 2006; Chi, Eisenhauer et al. 2006), others have demonstrated less benefit. A meta-analysis 
of fifty eight studies analyzing about 6900 patients demonstrated that maximal 
cytoreduction in advanced ovarian cancer led to only a modest improvement in outcomes, 
however, it was the use of platinum based chemotherapy which had the most pronounced 
effect (Hunter, Alexander et al. 1992).  
The results of various studies analyzing the outcomes of neoadjuvant chemotherapy in 
advanced ovarian cancer are summarized in table 1. 
 
Study type Author 
# 
Patients
Stage
Optimal 
cytoreduction (NAC 
VS. PDS) 
OS 
(NAC VS. PDS) 
Randomized 
control trial 
Vergote et al (Vergote, 
Trope et al. 2010) 
670 IIIc-IV
82% vs. 46% 
(p= NS) 
30m vs. 29m 
(p=0.98) 
Randomized 
control trial 
Kumar et al 128 IIIc- IV
83% vs. 13% 
(p<0.001) 
41m vs. 42 m 
(p=ns) 
Prospective non 
randomized  
Kuhn et al (Kuhn, Rutke  
et al. 2001) 
63 IIIc 
More in NAC group 
(p=0.004) 
42m vs. 23m 
(0.007) 
Retrospective 
Steed et al (Steed, Oza  
et al. 2006) 
116 IIIb-IV
48% vs. 14%  
(p<0.01) 
P=0.95 when 
adjusted for age 
and grade 
Retrospective 
Hou et al (Hou, Kelly  
et al. 2007) 
172 IV 
95% vs. 71% 
(p<0.001) 
31m vs. 20m 
(p<0.01) 
Retrospective 
Ansquer et al (Ansquer, 
Leblanc et al. 2001) 
54 IIIc- IV 91% vs. 82% 
Higher in NAC 
group (p<0.01) 
Non randomized 
prospective trial 
Giannopoulos  
et al (Giannopoulos,  
Butler-Manuel et al. 2006) 
64 IIIc-IV
82.9% vs. 62.1% 
(p=0.061) 
Not calculated 
Retrospective Schwartz, chambers 29 IIIc-IV Not calculated P= 0.26 
Retrospective Schwartz, Rutherford 265 IIIc-IV Not calculated 
1.09y vs. 2.18y 
(P=0.1578) 
Table 1. Studies comparing primary debulking surgery (PDS) to interval debulking after 
neoadjuvant chemotherapy (NAC), OS: overall survival 
2.3 Number of cycles of NAC 
In an analysis of patients treated with neoadjuvant chemotherapy, 18 patients were operated 
after three cycles of neoadjuvant chemotherapy and 32 patients received six cycles of 
neoadjuvant chemotherapy. There was no significant difference in survival after three and 
six cycles of chemotherapy (20 vs. 15 months, p = 0.27). The main factors influencing 
treatment results were optimal cytoreduction and tumor grade. The side effect frequency 
and profile was also similar in the two groups (Bidzinski, Danska-Bidzinska et al. 2005).  
3. Conclusion 
There is reasonable evidence to suggest that neoadjuvant chemotherapy has a role in 
carefully selected group of patients with advanced ovarian cancer, in whom primary 
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surgery will be impossible or suboptimal due to existing comorbidities or extent of the 
disease. It has also been documented that patients undergoing neoadjuvant chemotherapy 
followed by surgery have a much better quality of life and require a shorter time to return to 
baseline. Moreover, neoadjuvant chemotherapy demonstrates clear benefit in terms of 
shorter hospital stays and lesser post-operative morbidity. Although, the landmark trial 
investigating the role on neoadjuvant chemotherapy in advanced ovarian cancer did not 
show a survival advantage, it does demonstrate that neoadjuvant chemotherapy increases 
chances of optimal cytoreduction. In such patients, primary chemotherapy followed by 
surgical resection is an acceptable management option.  
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